1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Allogeneic haematological stem cell transplantation (HSCT) has developed into
immunotherapy. Donor CD4+, CD8+ and natural killer (NK) cells have been reported to …

Background In this trial of the treatment of newly diagnosed multiple myeloma, we compared
a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an …

The full potential of a graft-versusmyeloma effect after allogeneic hematopoietic cell
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …

We report the outcome of 229 patients who received an allograft for myeloma with reduced-
intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood …

Recommendations are based on a review of the literature using Medline, PubMed, Embase,
Central, Web of Science searches from the beginning of 2013 up to July 2019. The following …

Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports
of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic …

Despite recent advances, allografting remains the only potential cure for myeloma. From
July 1999 to June 2005, 100 newly diagnosed patients younger than 65 years were enrolled …

Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy
of multiple myeloma (MM) is presented and critically evaluated in this systematic evidence …

Although functionally competent cytotoxic, T cells are frequently observed in malignant
diseases, they possess little ability to react against tumor cells. This phenomenon is …